Fig. 6: 3BNC117-Db induces NK cell activity and elimination of infected cells in hIL-15^TgNSG mice.

a, Frequencies of human CD4⁺ T cells and CD3⁻CD56⁺ NK cells in the peripheral blood at 12 weeks posttransfer of human fetal liver and thymus tissues into hIL-15^TgNSG mice. Mice were randomly assigned to two groups corresponding to treatment with H2-Db (n = 9) or 3BNC117-Db (n = 9) at day 33 postinfection. Data are reported as the percentage of PBMCs that expressed the indicated markers (mean, s.d.). b, Schematic showing hIL-15^TgNSG mice infected with HIV_SUMA at 12 weeks postreconstitution as in a, administered ART from day 14 to day 49 postinfection, injected intraperitoneally with H2-Db or 3BNC117-Db daily between day 33 and day 43 postinfection, sampled for peripheral blood on days 0, 7, 14, 21, 28, 35, 42 and 49 postinfection (small black arrows) and euthanized at day 49 postinfection for collection of splenic tissue. c, HIV-1 RNA copies per ml of plasma (far left), percentage of CD4⁺ T cells (middle left), percentage of CD3⁻CD56⁺ lymphocytes (middle), percentage of HLA-DR⁺ NK cells (middle right) and percentage of CD57⁺ NK cells (far right) from day 0 to day 49 postinfection of hIL-15^TgNSG mice. Data are shown as both individual values (top) and average values (bottom) for both the H2-Db- and 3BNC117-Db-treated mice (mean, s.d.): H2-Db (n = 9), 3BNC117-Db (n = 9). The significance was determined by two-way ANOVA followed by Šídák’s test for multiple comparisons: ^*P < 0.05, ^**P < 0.01, ^***P < 0.001, ^****P < 0.0001. d, Frequencies of intact provirus⁺ CD4⁺ T cells, 5′-deleted provirus⁺CD4⁺ T cells and 3′-deleted/hypermutated provirus⁺ CD4⁺ T cells in hIL-15^TgNSG mice at day 49 postinfection. Data are reported as HIV-1 copies per million human CD4⁺ T cells (mean, s.d.): H2-Db (n = 9), 3BNC117-Db (n = 9). The significance was determined by two-way ANOVA followed by Šídák’s test for multiple comparisons: ^***P < 0.001, ^****P < 0.0001. Comparisons between intact copies per million human CD4⁺ T cells percentage of CD3⁻CD56⁺ lymphocytes (middle left), percentage of HLA-DR⁺ NK cells (middle right) and percentage of CD57⁺ NK cells (far right) posttreatment (day 42).